ANDAs: Pre-Submission Facility Correspondence Related to Prioritized Generic Drug Submissions
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
June 16, 2025
June 16, 2025
44de7e09-5433-4834-a1c2-11c6a384c15e
Related Documents
Cover Letter Attachments for Controlled Correspondences and ANDA Submissions: Guidance for Industry
Guidance DocumentJune 5, 2023Center for Drug Evaluation and Research
Controlled Correspondence Related to Generic Drug Development
Guidance DocumentMarch 18, 2024Center for Drug Evaluation and Research
Cannabis and Cannabis-Derived Compounds: Quality Considerations for Clinical Research Guidance for Industry: Guidance for Industry
Guidance DocumentJanuary 23, 2023Center for Drug Evaluation and Research
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Subscribe to our newsletter
Get the latest updates and insights delivered to your inbox